Shandong will focus on supporting the development of new pharmaceutical industry

In the next three years, our province will focus on supporting the accelerated development of the new pharmaceutical industry, and the government departments will make comprehensive use of fiscal, tax, land, financial credit and other measures to make the annual growth rate of the new pharmaceutical industry more than 20% By 2012, the pharmaceutical industry structure of the whole province will be significantly optimized, high-end technologies such as bioengineering technology, information technology, nanotechnology, and traditional Chinese medicine modernization technology will be promoted and applied in the new pharmaceutical industry, and the scale of the new pharmaceutical industry will be significantly expanded This is what the reporter learned today from the provincial Conference on promoting the development of new pharmaceutical industry The five key provincial governments have recently issued policies to accelerate the development of the new pharmaceutical industry, aiming to optimize the structure of the pharmaceutical industry By 2012, the sales revenue of the whole province's pharmaceutical industry is planned to reach 250 billion yuan, including 50 billion yuan of the new pharmaceutical industry; cultivate a group of new pharmaceutical industry bases with strong competitiveness, form three enterprise groups with sales revenue of more than 10 billion yuan, and 30 new pharmaceutical enterprises with sales revenue of more than 1 billion yuan; build Shandong Province's major new drug creation center into the first-class drug innovation and development in China Platform, develop a batch of new drugs with independent intellectual property rights and market competitiveness, strive to have 50 new drugs and 50 high-tech medical devices on the market or enter clinical research In the next three years, the development of new pharmaceutical industry in our province will focus on five key points, namely, the development of biopharmaceuticals, marine drugs, chemicals, modern Chinese medicine and medical devices Biopharmaceuticals will strengthen the innovative research of biotechnological drugs and promote the industrialization of biotechnological drugs With the technical support of Ocean University of China and Shandong University, and the main research objects of marine animals and plants, marine symbiotic microorganisms and extreme environmental microorganisms, marine drugs vigorously develop a series of marine drugs such as antihypertensive, hypoglycemic, lipid-lowering, anti-tumor and health care Among the chemicals, the production of traditional preponderant APIs will be built into a world-class API base, product seriation will be promoted, and supporting intermediate production will be vigorously developed; major disease drugs will support a number of independent intellectual property rights and domestic and international priorities for the prevention and control of major diseases and infectious diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, diabetes, depression, hepatitis, AIDS, etc Large market prospect innovative drug industrialization projects and major technological innovation platform construction; new preparation drugs will encourage enterprises to absorb and re innovate, vigorously develop new dosage forms and new products of controlled release, targeted and transdermal absorption; new vaccine development focuses on supporting new anti-tumor, anti-virus, anti bacterial, anti parasitic, new rabies, new avian influenza and other research 。 Modern traditional Chinese medicine will develop key traditional Chinese medicine varieties and botanical medicines, promote the application of new technologies and processes such as biological enzyme bionic extraction, membrane separation and supercritical extraction in the research and development and production of traditional Chinese medicine, and follow the road of modernization of traditional Chinese medicine; support the secondary development of famous and excellent traditional Chinese medicine, and focus on the development of donkey hide gelatin series, honeysuckle series, ginkgo series, Danshen series, sanbian series and high-content western medicine Ginseng extract, etc Our province will consolidate the advantages of conventional medical devices and disposable sterile medical devices, vigorously develop new varieties of high-end medical devices, implantable devices, new packaging materials, etc., explore the international market, and form the largest and the highest grade production base of medical devices in China From 2010 to 2012, a special fund for new medicine development was set up in our province Every year, the provincial finance arranges a certain amount of funds to reward the achievements of major innovative drugs and technology research and development, as well as the project subsidies for the industrialization of new drugs, the promotion of advantageous products, and the construction of traditional Chinese medicine base The special funds are mainly used to support the innovation of enterprises, the research and development of innovative new medical achievements, the industrialization of new medicine and the promotion of advantageous products, and the construction of the production base of traditional Chinese medicine Technology centers and engineering technology centers at or above the provincial level with strong R & D capability, many achievements reserve, and significant achievements in key and prospective technology R & D, as well as class I new drugs, class II new drugs, class III new drugs, and class VI and above products of traditional Chinese medicine will receive financial rewards Medical technical service income exempted from business tax is listed in the key projects of the provincial new pharmaceutical industrialization and advantage product promotion plan If new land is needed, when determining the base price of land transfer, it can be implemented according to not less than 70% of the lowest price standard of industrial land transfer corresponding to the local land level, and at the same time, it can ensure the demand for construction land and give priority to the land use procedures For the research and development expenses incurred by pharmaceutical enterprises for the development of new technologies, new products and new processes, if no intangible assets are formed and included in the current profits and losses, on the basis of actual deduction according to the provisions, it can be calculated and deducted at 50% of the research and development expenses; if intangible assets are formed, it shall be amortized at 150% of the intangible assets Relevant enterprises engaged in technology development, technology transfer business and related technical service income are exempt from business tax We will encourage technological transformation of enterprises, implement policies such as value-added tax transformation and duty-free import of equipment, and exempt administrative and institutional fees of relevant enterprises if they can, or at the lowest level if they cannot.